Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    Ixmyelocel-T
Show Display Options
Rank Status Study
1 Recruiting An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T;   Other: Vehicle Control
2 Active, not recruiting An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
Condition: Critical Limb Ischemia
Interventions: Biological: Ixmyelocel-T;   Other: Vehicle Control
3 Completed Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Condition: Peripheral Arterial Disease
Interventions: Biological: autologous bone marrow cells;   Biological: electrolyte solution (without cells)
4 Active, not recruiting Cell Therapy for Craniofacial Bone Defects
Conditions: Cleft Palate;   Trauma
Interventions: Biological: Ixmyelocel-T;   Procedure: Autogenous Bone Grafting
5 Completed Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
Condition: Dilated Cardiomyopathy
Intervention: Biological: Cardiac Repair Cells (CRCs)
6 Completed Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Intervention: Biological: Cardiac Repair Cells (CRCs)
7 Completed
Has Results
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Condition: Alveolar Bone Loss
Interventions: Biological: Tissue Repair Cells (TRC);   Device: Control

Indicates status has not been verified in more than two years